Who we are
ADMdx specializes in brain image analysis to enable diagnosis, prognosis, and drug effect detection for Alzheimer's disease and various other forms of dementia. We provide pharmaceutical companies with powerful information to improve clinical trial success. ADMdx provides image data analysis and full CNS imaging study services with structural MRI, amyloid PET, tau PET, FDG PET, ASL, fMRI BOLD, and DTI. We are developing diagnostic products to enable early, accurate disease detection supporting optimal patient care.
News & events
ADMdx to present at the Tau2020 Conference on February 12
ADMdx will present findings regarding the presence of tau, an abnormal protein, in Alzheimer’s patients, at the Tau2020 conference to be held in Washington DC on February 12. This work describes the diverse burden of tau in individuals with Alzheimer’s disease, and relationships to brain atrophy, glucose metabolism, age, gender, and clinical status.
See full postADMdx to present insights to relationships between tau, glucose metabolism, and atrophy using PET and MRI imaging
ADMdx will present findings regarding relationships between tau, glucose metabolism, brain atrophy, and patient characteristics at the ADPD conference in April 2020. These analyses used a unique data set acquired through the Phase II study of the drug rasagiline in Alzheimer’s disease patients in collaboration with Dr. Jeffrey Cummings of the Cleveland Clinic. The data […]
See full postADMdx presents results of a Phase II clinical trial of rasagiline in collaboration with the Cleveland Clinic
Dawn Matthews, CEO, presented results of ADMdx’s analysis of image data for a Phase II clinical trial of the drug rasagiline in Alzheimer’s disease patients at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego. The trial was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health at the […]
See full postDawn Matthews, CEO, speaks at the Alzheimer’s Drug Discovery Foundation Nov. 1 luncheon
Dawn Matthews, ADMdx CEO, was one of three speakers in an invited panel presentation at the Alzheimer’s Drug Discovery Foundation (ADDF) luncheon on November 1, 2019 in New York. The panelists described the results of their studies, each focused on repurposing currently approved medications for use in Alzheimer’s disease. Ms. Matthews related the successful outcome […]
See full postNew results from ADMdx’s image analyses in Down syndrome published
New results from ADMdx’s collaborative work on the Down syndrome Biomarker Initiative (DSBI) study led by Dr. Michael Rafii of the University of Southern California has been published. These results show the correlation between imaging biomarkers and increases in NeuroFilament Light (NF-L), a blood-based marker of neurodegeneration. The manuscript is published in the journal Alzheimer’s […]
See full postADMdx to present results of dementia differentiation using MRI, FDG, and early frame amyloid imaging at AAIC
ADMdx will present the results of machine learning classification of different Alzheimer’s disease variants and non Alzheimer’s dementias using three different modalities: structural MRI, glucose metabolism using FDG PET, and early timeframes of amyloid PET scans. This work was conducted in collaboration with researchers from the Memory and Aging Center of the University of California, […]
See full postOur machine learning analysis of Traumatic Brain Injury image data to be presented at AAIC
ADMdx will present the results of machine learning classification of brain images from impaired and unimpaired boxers, and their differentiation from Alzheimer’s disease images, at the Alzheimer’s Association International Conference on July 22, 2018. This work was conducted in collaboration with Dr. Charles Bernick and other researchers at the Cleveland Clinic, using structural MRI scans […]
See full postADMdx awarded SBIR grant from the National Institute of Aging
ADMdx has been awarded a Small Business Innovation Research grant from the National Institutes of Aging, focused on the prediction of tau burden in the brain using MRI scans and machine learning. PET tracers for tau have made it possible to measure abnormal tau accumulation, one of the hallmark pathologies of Alzheimer’s disease. Using tau […]
See full postFindings published regarding the impact of Mediterranean diet on Alzheimer’s disease risk
The results of our collaborative work led by Dr. Lisa Mosconi at Weill Cornell Medical School have been published in the April issue of the journal Neurology. Findings showed that lower adherence to a Mediterranean diet was associated with progressive abnormalities in glucose metabolism (measured using FDG PET imaging) and in amyloid (measured using amyloid PET […]
See full postOur collaborative work led by Dr. Lisa Mosconi shows the benefit of Mediterranean diet in Alzheimer’s disease risk
Our collaborative work led by Dr. Lisa Mosconi of Weill Cornell Medical College has been published in the March issue of the British Medical Journal, titled “Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer’s disease: a cross-sectional study of middle-aged adults from the broader New York City area”. In this study, brain image […]
See full post